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Abstract: Deficient nutritional support and subsequent postnatal growth failure are major
covariates of short- and long-term outcome in preterm neonates. Despite its relevance,
extrauterine growth restriction (EUGR) is still prevalent, occurring in an important portion
of extremely preterm infants. Lipids provide infants with most of their energy needs, but also
cover specific supplies critical to growth, development and health. The use of human milk in
preterm neonates results in practices, such as milk storage, pasteurization and administration
by an infusion system. All of these pre-exposure manipulations significantly affect the final
extent of lipid deposition in the intestinal track available for absorption, but the impact of tube
feeding is the most significant. Strategies to shift earlier to oral feeding are available, while
adaptations of the infusion systems (inversion, variable flow) have only more recently been
shown to be effective in “in vitro”, but not yet in “in vivo” settings. Pre-exposure-related
issues for drugs and nutritional compounds show similarities. Therefore, we suggest that
the available practices for “in vitro” drug evaluations should also be considered in feeding
strategies to further reduce pre-exposure losses as a strategy to improve the nutritional status
and outcome of preterm neonates.
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1. Introduction
The nutritional management of preterm infants, especially in extremely preterm (<28 weeks)
or extremely low birth weight (<1000 g) infants, should aim to result in growth patterns that
approximate the patterns of intrauterine fetal growth [1]. Using this paradigm, extrauterine growth
restriction (EUGR) is still prevalent, occurring in a very relevant portion of extremely preterm
infants. Extrauterine growth restriction has been associated with significant caloric and protein deficits
that accumulate during hospitalization, but also with slower growth velocity and major neonatal
morbidities, including bronchopulmonary dysplasia, retinopathy of prematurity and subsequent impaired
neurodevelopment [2]. However, it is not so obvious how to disentangle the cause and consequence.
To illustrate this, we refer to a recent analysis on perinatal variables associated with extrauterine
growth restriction in a longitudinal study in four neonatal intensive care units (NICU)’s in Brazil [3].
Based on perinatal data of 570 very low birth weight infants (<1500 g), maternal hypertension, male
gender, growth restriction at birth, respiratory distress syndrome and length of hospital stay were
significantly associated with the weight Z-score at hospital discharge. Moreover, logistic regression
analysis (weight Z-score ď ´2 at hospital discharge) documented that the length of hospital stay, the
presence of respiratory distress syndrome, treated patent ductus arteriosus and growth restriction at birth
were retained in the final weight model [3,4]. These neonatal morbidities are commonly treated with
fluid restriction, resulting in associated caloric restriction [5]. To further stress the interaction between
disease and nutritional deficiency, respiratory disease in the first 28 days of life was the best predictor of
reduced growth velocity in a cohort of 1187 extremely (23–27 weeks) preterm neonates in a multivariable
model [6].
While the causes of postnatal growth restriction in preterm infants are multifactorial, it has been
estimated that about 50% of the variance in early postnatal growth can be attributed to nutrition [7].
This is because the nutritional intakes provided to extremely preterm (i.e., <28 weeks gestational age)
or extremely low birth weight (ELBW, i.e., <1000 g) neonates are commonly lower than recommended,
resulting in cumulative deficits in caloric accretion, in body weight, body length and head circumference
during later neonatal stay, at discharge and beyond [2]. Extrauterine growth restriction in these patients
is to a certain extent similar to the neonates with intrauterine growth restriction at birth. However, and in
contrast to the intrauterine variant, the extrauterine variant is a medically-induced, iatrogenic and likely
avoidable complication of preterm birth.
Overall, deficient nutritional support and the subsequent postnatal growth failure are major covariates
of both the short- and long-term outcomes of preterm neonates, but not always in a simple linear
relationship. Rapid postnatal weight (re)gain (“catch up growth”) following nutritional restriction is
associated with both positive effects on neurodevelopment outcome, as well as with the development
of insulin resistance and metabolic syndrome in later life [2,5]. It is likely that minimization of early
postnatal growth failure will decrease the need for catch-up growth and thereby decrease the risk of
developing cardiovascular risk factors while still maintaining the positive effects on neurodevelopment,
resulting in the concept of “early aggressive nutrition” [5,7].
Lipids provide infants with most of their energy needs. Consequently, dietary lipids are key for
preterm neonates, and this is not limited to attaining their energy needs (9 kcal/g fat), but also covering
essential supplies critical to growth, development and health. Besides quantitative aspects, qualitative
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aspects also matter [8–10]. The major portions of fat in human milk can be retrieved as triglycerides
or phospholipids, with only a limited amount of cholesterol. Long-chain polyunsaturated fatty acids
(LC-PUFAs) are crucial for normal development of the central nervous system and may have long-lasting
effects beyond the period of dietary insufficiency. Since the formation capacity of docosahexaenoic acid
(DHA) from α-linolenic acid in preterm neonates is limited and variable and because DHA is critical
for normal retinal and brain development in humans, DHA should be considered to be conditionally
essential and should also be present in lipid supplementation strategies in neonates, either parenteral or
enteral [8–10].
Based on the currently available information, it seems safe to start lipid emulsions from birth
onward at a rate of 2 g lipids/kg/day, although there is still the practice of using a more incremental
approach [10,11]. Mixed lipid emulsions, including those containing fish oil, seem to reduce nosocomial
infections in preterm infants and might reduce bile acid accumulation. Liver damage may be reduced by
decreasing or removing lipids from parenteral nutrition or may be reduced by using fish oil-containing
lipid emulsions containing high levels of vitamin E [10]. In early enteral studies, the amount of specific
lipids in formula was chosen to produce similar concentrations of arachidonic acid and DHA as in term
human milk. Recent studies report outcome data in preterm infants fed formula with DHA content
2–3-times higher than the current concentration. Overall, these studies show that providing larger
amounts of DHA supplements is associated with better neurological outcome [8–10].
Finally, the switch from parenteral to enteral nutrition warrants specific attention. Human milk is the
reference product and optimal for term neonates, but not for preterm neonates [12,13]. Fortification,
either standardized or individualized/targeted, is needed to cover the needs in preterm neonates [14–16].
The concept, including feasibility and the day-to-day variation in macronutrients (proteins 20%,
carbohydrates 13% and lipids 17%), of repeated human milk analysis and subsequent target fortification
has recently been discussed in this journal [17].
Unfortunately, there seems to be a very significant and clinically-relevant difference between the
lipid content in fresh human milk and the final amount of lipids administered to the intestinal track of
preterm neonates.
This commentary aims to focus on these pre-exposure fat losses to further stimulate research in
this specific field. We hereby aim to make the link with population-specific drug formulations and
administration practices.
2. Development of Oral Feeding Skills
Preterm infants are still immature, including their neurologic, gastro-intestinal and respiratory system.
As a part of this, the coordination of suck-swallow-respiration is not yet mature. As a result, they have
difficulties establishing oral feeding. Until they achieve adequate feeding skills, tube feeding is used.
Failure to establish oral feeding can lead to poor nutritional status and growth failure [18,19]. Moreover,
neurodevelopmental and growth outcome in the long term depend on oral feeding competence [20].
Although there is a general consensus on the need to make the transition to oral feeding as soon as
possible, a consensus on how to proceed is lacking. Feeding practices depend on local practices and
beliefs [21,22]. Human milk is recommended for enteral nutrition of infants, especially preterm infants,
for whom it is particularly beneficial [23]. Human milk can also help to achieve feeding milestones
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earlier compared to formula-fed infants [24]. This can be attributed to better feeding tolerance,
immunoprotective and growth factors and maturation of immature host defenses [16,23].
Most preterm infants achieve oral feeding skills by 36–38 weeks postmenstrual age. However,
extremely preterm infants (<28 weeks) and infants with medical complications need more time to
attain this milestone [19,25]. Infants with younger gestational age have a significant delay in feeding
initiation [19,24]. The most remarkable delay lies in the initiation, suggesting a maturational delay
in neurological, gastrointestinal and/or suck-swallow-respiration coordination functions. Strikingly,
when these younger preterm infants initiate oral feeding, they need the same time (3–5 weeks) to
achieve full oral feeding [24]. Attaining early first and full enteral feeding seems to facilitate later
feeding milestones [19]. In a recent study, Zhang quantified the impact of non-nutritive sucking
and oral stimulation on feeding performance in a randomized controlled trial setting. The authors
hereby quantified that non-nutritive sucking and oral stimulation reduced the median transition time
(i.e., introduction of oral to independent oral feeding) by about one week [26]. Focusing on the
infant’s feeding readiness seems to be important to achieve full oral feeding earlier. In this cue-based
feeding practice, assessment of early feeding skills is essential to select effective therapeutic feeding
interventions [27]. In medical conditions, like neurological diseases (periventricular leukomalacia,
Intraventricular bleeding Grades 3–4) or bronchopulmonary diseases, oral feeding development is
commonly delayed [24]. This is particular the case in severe cases of bronchopulmonary disease and
in former preterm neonates following surgically-treated patent ductus arteriosus.
3. The Fate of Fat: Pre-Exposure Fat Losses during Nasogastric Tube Feeding
The need to use gavage feeding of preferably human milk in the setting of neonatal intensive care
results in the practice of milk storage, pasteurization and subsequent administration by an infusion
system [5]. However, infusion systems used for enteral nutrition support in preterm neonates result
in a significant reduction of lipids (up to 40%) delivered to the intestinal track [28–31]. These major
losses of lipids further add to initially more limited losses due to pasteurization [32–34], freezing and
thawing [34,35].
The extent of the impact and consecutive losses in lipids has been summarized in Figure 1. In addition
to these quantitative effects, there are also some observations on qualitative effects, since adherence of
medium-chain fatty acids to feeding tubes during gavage feeding for fortified human milk have also
been described [36]. We were struck by the limited number of efforts made to prevent the major losses
(80% of the pre-exposure lipid losses) related to the tube feeding techniques themselves, when compared
to the observations on pasteurization or freezing/thawing (relative losses 20%), although the impact of
pasteurization is not limited to lipid content only.
Avoidance of tube feeding by earlier introduction of oral feeding and preventive strategies related to
switching from tube feeding to oral feeding have been discussed earlier. Avoidance of pasteurization
in the setting of mother’s own milk seems a very reasonable option, when there is sufficient focus on
collection, storage and labeling procedures to ensure the safety and quality of expressed milk [37].
Pasteurization does not only affect the lipid content, but also other characteristics, including bactericidal
functions or functional elimination of lipase activity present in fresh human milk [38]. In preterm
infants fed pasteurized human milk or formula, one week of treatment with recombinant human bile
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salt-stimulated lipase (rhBSSL) was well tolerated and significantly improved growth and long-chain
polyunsaturated fatty acid absorption compared to placebo [38]. The mean weight increase was 17%
higher (16.86 vs. 13.93 g/kg/day for one week) in the cases exposed. Unfortunately, the preliminary
communication of the results of the subsequent phase III study (LAIF, lipase added to infant feeding, 410
infants, four weeks of exposure) failed to confirm these differences (16.8 vs. 16.6 g/kg/day, p = 0.49) [39].
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Figure 1. The progressive losses of fat content (mg%) in mother’s milk during the chain of 
processes commonly used in the NICU setting. The data were pooled from the publications 
of Vieira et al. on the impact of pasteurization and freezing/thawing and of Jarjour et al. on 
the impact of mixing of human milk (inversion, variable flow) during continuous infusion 
[29,34]. 
In contrast, concepts to avoid major lipid losses due to tube feeding itself remained underexplored. 
At least the most recent Cochrane analysis on continuous vs. intermittent bolus milk feeding for premature 
infants (<1500 g) could not document any benefit (e.g., growth, necrotizing enterocolitis) [40]. However, 
a potential relevant technical concept has been reported in this journal [29]. To address the separation of 
fat from aqueous milk in the feeding bag, an in vitro motorized feeding bag inverter was developed.  
Three inversions of the milk-containing bag were applied during ten seconds, followed by a three-minute 
interval of rest before the next set of inversions. Additionally, the authors designed a circulation loop to 
circulate fast-flowing milk through the tubing back to the feeding bag in order to minimize fat separation 
and adherence in the ePumpTM infusion set tubing. Compared to the standard practices (60% of milk 
fat), the use of a feeding bag inverter and a tubing circulation loop delivered about 90% of milk fat when 
used in conjunction with a commercial continuous infusion system. This report was limited to in vitro 
observations, but warrants prospective evaluation, preferably by randomized controlled trials with a 
focus on relevant outcome variables (weight gain, neurocognitive outcome) [29]. Recently, Tabata et al. 
illustrated fat loss in human milk, the influence of added nutrients and the method of infusion [41]. Fat 
loss was greater when human milk was administered with a vertical feeding bag, compared to a 
 
Figure 1. The progressive losses of fat content (mg%) in mother’s milk during the chain of
processes commonly used in the NICU setting. The data were pooled from the publications
of Vieira et al. on the impact of pasteurization and freezing/thawing and of Jarjour et al. on the
impact of mixing of human milk (inversion, variable flow) during continuous infusion [29,34].
In contrast, concepts to avoid major lipid losses due to tube feeding itself remained underexplored. At
least the mo recent Cochr ne analysis on continuous vs. intermitt nt bolus milk feeding for premature
infant (<1500 g) could n t document any benefit (e.g., growth, necrotizing enterocolitis) [40]. However,
a potential relevant tech ical onc p has en reported in this journal [29]. To address the separation
of fat from aqueous milk in the fe ding bag, an in vitro motorized feeding bag inverter wa developed.
Three inversions of the milk-containing bag were applied during ten s conds, followed by a three-minute
interval of rest before the next set of inversions. Additionally, the authors esigned a circulation loop to
circul te fast-flowing milk through the tubing back to the feeding b g in or r to minimize f t separation
and adh rence in the ePumpTM infusion set tubing. Compared to the standard practices (60% of milk
fat), the use of a feeding bag inverter and a t i circulation l op delivere about 90% of milk fat
when used in conjunction with a commercial continuous infusion system. This report was limited to
in vitro observations, but warrants prospective evaluation, preferably by randomized controlled trials
with a focus on relevant outcome variables (weight gain, neurocognitive outcome) [29]. Recently,
Tabata et al. illustrated fat loss in human milk, the influence of added nutrients and the method of
infusion [41]. Fat loss was greater when human milk was administered with a vertical feeding bag,
compared to a horizontal syringe, providing a benefit for the horizontal syringe method of infusion.
Whenever possible, the shortest time of infusion is preferred (e.g., gravity driven). For those infants who
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do not seem to tolerate their feeds well, Tabata’s study provides evidence that the addition of human
milk fortifier (HMFand/or cream) increases the fat concentration of the human milk when given over a
one-hour infusion. Potential strategies to reduce pre-exposure fat losses are summarized in Figure 2.
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Figure 2. Strategies to reduce pre-exposure fat losses during nasogastric tube feeding. 
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Relevant efforts have been made to improve the relative limited (20%) losses on tube feeding
and pre-exposure manipulation, while there is still much to gain through improvements (80%
of relative fat losses) in administration techniques.
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hen riting this co entary, e ere struck by the si ilarities in product develop ent in the
fields of developmental pharmacology and developmental nutritional support. Both aim to develop
more population-tailored products and, therefore, need to integrate the maturational needs of the
preterm neonate (e.g., maturational absorption, maturational caloric needs), as well as pre-ad inistration
anipulations that also ay affect the real, final exposure to a given co pound (product stability,
co patibility, adherence to tubing). Drug administration in neonates presents a series of challenges
that relate to the pathophysiology of the neonate (dose selection, developmental pharmacokinetics and
dynamics) [44,45] and the systems or methods to administer these doses accurately. To illustrate this
for intravenous formulations, several challenges arise, e.g., slow flow rates, small volumes, dead space
volume and limitations on the total volume. hile there is a reasonable understanding of neonatal
pharmacokinetics [46], an appreciation of the substantial delay and variability in the rate of drug delivery
from the intravenous line to the neonate is often lacking. Besides drug-related issues, like compatibility
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or density, delivery-related issues (e.g., dead space, fluid flow dynamics, inline filters or tubing diameter,
components in the tubing, flow rate) for either drugs or nutritional compounds do have similar issues.
We suggest that the available practices for “in vitro” drug evaluations should be considered to further
improve the nutritional status and outcome of preterm neonates. For example, the potential impact of,
e.g., simultaneous administration with milk or adherence to the nasogastric tube of drug formulations
has also been recognized by the authorities involved in drug registration, since this is included in their
guidelines [47].
5. Conclusions
Deficient nutritional support and subsequent postnatal growth failure are major covariates of
short- and long-term outcome in preterm neonates. Despite its relevance, extrauterine growth restriction
(EUGR) is still prevalent, occurring in an important portion of extremely preterm infants. Driven by (i)
the need to switch as soon as possible from parenteral to enteral feeding, (ii) in the setting of preterm
neonates who are not yet able to tolerate oral intake and with (iii) human milk that is suboptimal in
preterm neonates, nasogastric tube feeding of fortified, manipulated human milk (freezing and thawing,
pasteurization) is the standard approach until preterm neonates develop the capacities for full oral
intake. Unfortunately, all of these pre-exposure practices significantly affect the final extent of lipid
disposition in the intestinal track available for absorption, with the use of tube feeding being the most
significant contributor.
Clearly, strategies to shift earlier to oral feeding (e.g., the impact of nonnutritive sucking and of oral
stimulation on feeding performance in preterm infants, cue-based feeding) need to be a high priority.,
Studies on the impact of pasteurization are available, but may not be relevant in the setting of mother’s
own milk when there is sufficient focus on collection, storage and labeling procedures to ensure the
safety and quality of expressed milk. In contrast, and despite the fact that the use of tube feeding is
the most significant contributor, studies on adaptations of infusion systems (inversion, variable flow)
have only more recently been shown to be effective in “in vitro”, but not yet in “in vivo” settings. Since
pre-exposure related issues for drugs or nutritional compounds show similarities, we suggest that the
available practices for “in vitro” drug evaluations should be considered to further improve the nutritional
status and outcome of preterm neonates.
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